Medigen Biotechnology Corp. (TPEX:3176)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Nucleic Acid Inspection Department	269.26M	64.84M	61.73M	83.79M	98.34M
Nucleic Acid Inspection Department Growth	315.27%	5.05%	-26.33%	-14.80%	-0.36%
New Drug and Vaccine Development Department	613.17M	605.64M	389.62M	365.04M	3.28B
New Drug and Vaccine Development Department Growth	1.24%	55.44%	6.73%	-88.85%	-
Cell Therapy Department	317.00K	9.45M	-	600.00K	11.98M
Cell Therapy Department Growth	-96.65%	-	-	-94.99%	2.14%
Generic Drugs, Medical Beauty Products and Health Food Departments	700.07M	695.08M	709.07M	606.52M	536.53M
Generic Drugs, Medical Beauty Products and Health Food Departments Growth	0.72%	-1.97%	16.91%	13.05%	6.22%
Adjustment and Elimination	-321.00K	-2.31M	-2.70M	-	-
Total	1.58B	1.37B	1.16B	1.06B	3.92B
Total Growth	15.28%	18.57%	9.64%	-73.08%	537.17%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Taiwan	1.54B	1.34B	1.15B	1.01B	3.85B
Taiwan Growth	14.91%	17.25%	14.03%	-73.87%	608.39%
Mainland China	7.21M	4.44M	6.30M	-	-
Mainland China Growth	62.26%	-29.42%	-	-	-
Other	30.57M	23.99M	4.96M	10.97M	20.79M
Other Growth	27.43%	383.88%	-54.82%	-47.22%	-33.90%
China	-	-	6.30M	39.59M	53.04M
China Growth	-	-	-84.10%	-25.36%	29.81%
Total	1.58B	1.37B	1.16B	1.06B	3.92B
Total Growth	15.28%	17.93%	10.23%	-73.08%	537.17%

Source: S&P Global Market Intelligence.